| Ytd | 22.14% | |
| 1y | -49.61% |
| Open | 0.72 | Prev Close | 0.72 | Low | 0.72 | High | 0.72 | Mkt Cap | 23.59M |
| Vol | 0.00 | Avg Vol | 1.76M | EPS | -0.90 | P/E | -0.80 | Forward P/E | -0.91 |
| Beta | -0.57 | Short Ratio | 3.82 | Inst. Own | 13.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.80 | 200-d Avg | 0.83 | 1yr Est | 0.95 |
CYTH News
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and th
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investiga
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Niemann-Pick disease - Pipeline Insight, 2024" clinic
Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.26 per share versus the Zacks C
MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYT
NEW YORK , Aug. 22, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"),
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.21 per share versus the Zacks C
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and th
On Monday, 76 companies set new 52-week lows.
During Friday's session, 574 stocks hit new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 351 stocks hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Friday, 209 companies set new 52-week lows.
Gainers INVO Bioscience, Inc. (NASDAQ: INVO) shares rose 108.4% to $6.48 in pre-market trading af
Gainers Synthetic Biologics, Inc. (NYSE: SYN) shares climbed 100% to close at $1.00 on Tuesday af
Friday's session saw 466 companies set new 52-week highs.